LexBlog IP

AUGUST 16, 2023

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

LexBlog IP

AUGUST 30, 2023

It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S. market on March 7, 2025, if approved by FDA.

Settlement 52

Settlement Confidentiality Marketing Marketing 52

LexBlog IP

MARCH 6, 2024

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. The agreement allows Biocon to launch in the United States in February 2025, pending FDA approval. 10,961,307, which claims methods of treating ulcerative colitis with ustekinumab. Amgen secured a U.S.

Marketing 52

Marketing Marketing Settlement Licensing 52

SpicyIP

JULY 8, 2024

Here is our recap of last week’s top IP developments including summary of the posts on the DHC’s direction to frame a code of conduct for Patent and Trademark Agents, MHC’s decision on prior arts, and the settlement between Dabur and Dhruv Rathee of their trademark and copyright dispute. Anything we are missing out on?

Invention 59

Invention Art Trademark Patent Application 59

Bio Law Blog

JUNE 21, 2020

settled three Inter Partes Review (IPR) proceedings concerning patents covering Alexion’s blockbuster humanized monoclonal antibody drug Soliris®, with Amgen obtaining a royalty-free license for marketing a biosimilar prior to expiration of the patents at issue. The patents at issue are U.S. Patent Nos.

Marketing 52

Marketing Marketing Settlement Patent 52

SpicyIP

MARCH 15, 2024

This post does not, in any manner, get into the arena of willingness or unwillingness of defendants to enter into a licensing agreement. Background The Petitioner, InterDigital (“ID”), initiated patent infringement proceedings against Oppo, One Plus and Redme (“defendants”) concerning 8 standard essential patents.

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

The IPKat

FEBRUARY 29, 2024

Sony maintains that the worldwide copyright for the recordings is held by Experience Hendrix LLC and Authentic Hendrix LLC, who license the rights to exploit and distribute the recordings to them. It is likely therefore that it will stand to be determined by a High Court judge some time in 2025.

Copyright 108

Copyright Reporting Contracts Settlement 108